Program Schedule

Time Topic Speaker
09:30-10:00 Registration
10:00-10:30 Opening Remarks & ProBio Introduction 주문경 상무
Head of Korea Business
Development, ProBio
10:30-11:00 Navigating the Successful CAR-T Roadmap from IND to BLA: Essential Lentiviral Vector CMC Strategies
11:00-11:20 Securing Commercial Grade LVV Supply to Achieve Market Approval for CAR-T Therapies 김형철 부사장
Executive Vice President,
Head of R&D Center, Curocell
12:00-13:00 Lunch and Networking
13:00-13:40 From Vector Backbone to Process: Systematic Design and Development Strategies for In Vivo CAR-T Lentiviral Vectors Yuefeng Li
Sr. Scientist, LVV Process Development & Vector R&D, ProBio
13:40-14:10 Bridging China IITs to IND: Translational CMC Strategies for CGT Therapies through an End-to-End IIT Ecosystem Xingwen Li
Manager, CGT Technology Center, ProBio
14:10-14:40 Coffee Break and Networking
14:40-15:20 Exploring Regulatory Strategies to Accelerate CGT Drug Development Tina Yu
Sr. Director, Regulatory Affairs Dept., ProBio
15:20-15:40 TBD China CGT Biotech Company
15:40-16:00 Lucky Draw & Closing Remarks

Speakers

Jennifer Ju

주문경 (Jennifer Ju)

Head of Korea Business Development, ProBio

  • Head of business development in Korea with expertise diversity applications of cell and gene therapy expert including regulatory, biologics
  • +20 years experience drug discovery, biologics upstream process development expert, and CGT process development expert
  • Serving as a member of the CARM Education Committee, M.S. from Seoul National University
Hyung Cheol Kim, Ph.D.

김형철 (Hyung Cheol Kim, Ph.D.)

Executive Vice President, Head of R&D Center, Curocell

  • Leads CAR-T therapy development at Curocell with extensive experience across biopharmaceuticals and biosimilars
  • Previously led biosimilar development projects at LG Chem
  • Ph.D. from the University of Texas at Austin; B.S. and M.S. from Seoul National University
Kevin Chen, Ph.D.

Kevin Chen, Ph.D.

Head of mRNA Business Dept., ProBio.

  • 10+ years of experience in plasmid preparation, mRNA synthesis and LNP encapsulation
  • Led mRNA and plasmid service teams, supporting IIT and IND-stage projects
  • Author of 15+ peer-reviewed publications, including papers in Nature and Cancer Cell
Yuefeng Li, Ph.D.

Yuefeng Li, Ph.D.

Sr. Scientist, LVV Process Development & Vector R&D, ProBio

  • Expertise in lentiviral vector design and novel envelope development
  • Experienced in lentiviral vector research, including postdoctoral training at Guangzhou Lab
  • Ph.D. in Cellular and Molecular Medicine from the University of Ottawa
Xingwen Li, Ph.D.

Xingwen Li, Ph.D.

Manager, CGT Technology Center, ProBio

  • Provide technical support and consultation for CGT clients
  • Broad experience across CGT modalities, including AAV, oncolytic viruses, CAR T, mRNA, and others
  • Ph.D. in Life Sciences from Hokkaido University
Tina Yu

Tina Yu

Sr. Director, Regulatory Affairs Dept., ProBio

  • 19+ years of experience in regulatory affairs and GMP audits
  • Led 200+ IND and 10+ BLA approvals across FDA, EMEA, and NMPA
  • Key contributor to China’s first NDA approval for a COVID-19 neutralizing antibody

Event Information

1. 컨펌(확정) 메일은 신청 시 남겨주신 메일로 7월 13일(월) 일괄 발송됩니다. 이후 등록 건은 48시간 내에 순차 발송될 예정입니다.

2. 사전등록 컨펌 메일을 받으신 분에 한하여 입장이 가능하며, 당일 현장 등록은 어려운 점 양해 부탁드립니다.

3. 행사 당일 일부 세션 녹화 및 현장 스케치 사진 촬영이 진행되며, 촬영된 자료는 행사 기록 및 홍보 목적으로 활용될 수 있습니다.

4. 본 행사는 무료로 진행되며, 점심 식사, 다과 및 기념품이 제공됩니다.

* 오찬(한식 도시락) 및 다과가 제공될 예정이며, 메뉴는 계절에 따라 변경될 수 있습니다.

Directions to the Venue

Directions to the Venue

Contact Us

기타 문의 사항이 있으신 경우, 이메일([email protected])로 연락 주시기 바랍니다.